Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Trifarotene Cream in Acne Vulgaris
NCT05550337Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2022
- Primary completion
- May 2023
- Countries
- 1
01
Overview
A Phase 3 trial of CD5789 cream vehicle in acne vulgaris, sponsored by Teva Pharmaceutical Industries Ltd.. Started Sep 2022; status: completed.
02
Drugs
CD5789 cream vehicle
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05550337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550337.